Vor Biopharma (NASDAQ:VOR) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research report report published on Thursday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $30.00 target price on the stock.

A number of other brokerages have also recently commented on VOR. JPMorgan Chase & Co. cut their target price on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. Citigroup initiated coverage on shares of Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 price objective on the stock. Wedbush began coverage on shares of Vor Biopharma in a research note on Tuesday, November 25th. They issued a “neutral” rating on the stock. Finally, TD Cowen initiated coverage on shares of Vor Biopharma in a report on Wednesday, December 17th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $62.11.

Vor Biopharma Stock Up 1.3%

NASDAQ:VOR opened at $13.17 on Thursday. The company has a market capitalization of $137.10 million, a PE ratio of -0.03 and a beta of 1.99. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The stock’s 50 day moving average price is $14.36 and its 200 day moving average price is $19.39.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new position in Vor Biopharma during the 4th quarter worth approximately $36,000. Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new position in Vor Biopharma during the second quarter worth $66,000. Chung Wu Investment Group LLC acquired a new position in Vor Biopharma during the fourth quarter worth $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in Vor Biopharma in the fourth quarter worth $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).